Lisa Pappas-Taffer, Misha Rosenbach, Emily Y. Chu. (2013) The Cutaneous Side Effects of Selective BRAF Inhibitors and Anti-CTLA4 Agents: the Growing Role of the Dermatologist in the Management of Patients with Metastatic Melanoma. Current Dermatology Reports 2 , 84-100 /...
HLX208 has a proprietary new chemical structure distinct from other marketed BRAF inhibitors. It exhibited a single crystal morph, high bioavailability, and excellent anti-tumour efficacy in preclinical studies, eyeing to be ...
Single-agent BRAF inhibitors are inefficient in treating an advanced form of cancer because of the quick development of resistance over less than a year of treatment. Dehydration, chills, fever, and rash are common side effects associated with single-agent BRAF inhibitors. MAPK independent development...
but it is also known to go wrong, or mutate, in several types ofcancer, including types of bowel, brain and skin cancer. A few BRAF inhibitor drugs have already proved effective in treating patients. However, these 'first generation' BRAF inhibitors do not work on all BRAF mutated cancers ...
The development of keratinocytic skin tumors, presumably attributable to paradoxical activation of the MAPK pathway, represents a relevant side effect of targeted therapies with BRAF inhibitors (BRAFis). The role of cutaneous papillomavirus infection in BRAFi-associated skin carcinogenesis, however, is ...
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment Jing Wei Wenke Li Ming Liu Molecular Cancer (2024) A fractional-order model for optimizing combination therapy in heterogeneous lung cancer: integrating immunotherapy and targeted therapy to minimize side effects David Amilo...
inhibitors. It works by blocking the action of an abnormal protein that signals cancer cells to multiply. This helps to slow or stop the spread of cancer cells. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. It may stop the growth of cancer cells ...
However, systemic inhibition of BRAF by small molecule drugs in cancer patients results – paradoxically – in increased wild-type BRAF activity in healthy tissue, causing side-effects and even the formation of new tumors. Here we show the development of BRAFV600E kinase inhibitors of which the...
targeting/lowering of CXCL8 levels is known to produce beneficial effects in thyroid cancer. Interestingly, a previousin vivostudy showed that patients with melanoma harboring the BRAFV600E mutation experience a significant decrease in the circulating levels of CXCL8 while treated with BRAF-inhibitors...
BRAF inhibitors alone showed stimulatory effects on T cells, potentially through paradoxical activation of ERK24. In contrast, MEK inhibitors led to partial and transient inhibition of T cell proliferation and potentially induced regenerative stem cell-like memory CD8+T cells25,26, which might...